VERAVera Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · veratx.com

32.28USD0.00%Mkt Cap: 2.33B $P/E: —3d ago

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a ful…

Headline	Source	Time
Older
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch	MarketBeat	Jul 11
Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?	Simply Wall St.	Jul 10
Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval	Simply Wall St.	Jul 10
Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run	Simply Wall St.	Jul 10
Sector Update: Healthcare Stocks Gain Late Afternoon	MMT Newswires	Jul 7
🔎 Under the Radar: Vera Stock Jumps as Kidney-Disease Drug Approved by FDA	The Wall Street Journal	Jul 7
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics	Stocktwits	Jul 7
Vera Therapeutics wins FDA nod for closely watched kidney disease drug	BioPharma Dive	Jul 7
Vera Therapeutics Shares Climb Ahead of FDA Decision on Atacicept (VERA)	InvestorsHub	Jul 6
Scilex, Vera Therapeutics rise premarket; Strategy gains	Investing.com	Jul 6
VERA Stock Rallies Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug – Retail Sees 35% Potential Upside	Stocktwits	Jul 6
Is Vera Therapeutics, Inc. (VERA) A Good Stock To Buy Now?	IInsider Monkey	Jul 4
FDA Progress Could Send This Biotech Stock Soaring To New Heights	IInsider Monkey	Jul 3
3 Biotech Firms With Major Potential Catalysts in the Coming Months	MarketBeat	Jun 21
Vera Therapeutics (VERA) Appears Attractive After Latest FDA Agreement	IInsider Monkey	Jun 17
Will FDA Alignment on Atacicept’s eGFR Plan Reshape Vera Therapeutics’ (VERA) IgA Nephropathy Narrative	Simply Wall St.	Jun 8
A Look At Vera Therapeutics (VERA) Valuation After FDA Alignment On Accelerated IgA Nephropathy Trial Analysis	Simply Wall St.	Jun 8
Sector Update: Healthcare Stocks Softer Late Afternoon	MMT Newswires	Jun 2
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment	Stocktwits	Jun 2
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing	Motley Fool	May 26

VERAVera Therapeutics, Inc.

Industry Peers